We are live on ! Find out more
GHDX

Genomic Health, Inc.
GHDX

Delisted

GHDX was delisted on the 7th of November, 2019.

Back to rankings

134 hedge funds and large institutions have $870M invested in Genomic Health, Inc. in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

26% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 42

13% more capital invested

Capital invested by funds: $772M → $870M (+$97.6M)

3% more funds holding

Funds holding: 130 → 134 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $220K

Holders
134
Holders Change
+4
Holders Change %
+3.08%
% of All Funds
3.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
53
Reduced
42
Closed
10
Calls
$1K
Puts
$220K
Net Calls
-$219K
Net Calls Change
+$148K

Top Buyers

Rank Fund Capital Flow
1
CWAM
Columbia Wanger Asset Management
Illinois
+$13.1M
2
EAM
Eagle Asset Management
Florida
+$8.11M
3
Charles Schwab
Charles Schwab
California
+$6.83M
4
NI
Numeric Investors
Massachusetts
+$3.18M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.11M

Top Sellers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$15.9M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$7.1M
3
BC
Broadfin Capital
New York
-$7M
4
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$6.74M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$625K +$1.53K +55 +0.3%
KB
77
Kimelman & Baird
New York
$620K – – –
FNBOO
78
First National Bank of Omaha
Nebraska
$609K +$65.2K +2,340 +12%
New York State Common Retirement Fund
79
New York State Common Retirement Fund
New York
$604K +$97.5K +3,500 +20%
Allianz Asset Management
80
Allianz Asset Management
Germany
$565K -$140K -5,020 -20%
Ameriprise
81
Ameriprise
Minnesota
$533K +$513K +18,426 New
State Board of Administration of Florida Retirement System
82
State Board of Administration of Florida Retirement System
Florida
$511K – – –
IPC
83
Independent Portfolio Consultants
Florida
$504K -$5.01K -180 -1%
DekaBank Deutsche Girozentrale
84
DekaBank Deutsche Girozentrale
Germany
$489K – – –
PPA
85
Parametric Portfolio Associates
Washington
$462K -$90.8K -3,258 -17%
First Trust Advisors
86
First Trust Advisors
Illinois
$398K +$384K +13,778 New
AL
87
Airain Ltd
Guernsey
$397K +$383K +13,734 New
Manulife (Manufacturers Life Insurance)
88
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$386K +$2.23K +80 +0.6%
MLICM
89
Metropolitan Life Insurance Company (MetLife)
New York
$383K – – –
SKK
90
Shepherd Kaplan Krochuk
Massachusetts
$383K – – –
NFA
91
Nationwide Fund Advisors
Ohio
$345K – – –
Citigroup
92
Citigroup
New York
$333K +$71K +2,548 +28%
AIG
93
American International Group
New York
$311K +$446 +16 +0.1%
AAM
94
Azzad Asset Management
Virginia
$299K +$7.97K +286 +3%
UBS Group
95
UBS Group
Switzerland
$283K -$41.2K -1,480 -13%
UBS AM
96
UBS AM
Illinois
$275K – – –
Envestnet Asset Management
97
Envestnet Asset Management
Illinois
$234K +$155K +5,547 +218%
LNWWM
98
Laird Norton Wetherby Wealth Management
California
$229K +$220K +7,910 New
Bank of America
99
Bank of America
North Carolina
$227K -$164K -5,881 -43%
SCM
100
Stonebridge Capital Management
California
$223K +$215K +7,705 New
2 3
4
5 6

GHDX Hedge Fund Activity: Q3 2016 in Review

134 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2016, worth a combined $870M — up 13% from $772M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GHDX positions and 10 closed out — a net gain of 4 holders — while 53 added to existing stakes and 42 trimmed.

The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $13.1M. The largest seller was Baillie Gifford & Co, cutting an estimated $15.9M.

  • 134 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2016, up from 130 in Q2 2016.
  • Funds reported $870M of Genomic Health, Inc. stock for Q3 2016, up 13% quarter-over-quarter.
  • 14 funds opened new Genomic Health, Inc. positions in Q3 2016 and 10 closed out, a net change of +4 holders.
  • The largest Genomic Health, Inc. buyer in Q3 2016 was Columbia Wanger Asset Management, an estimated $13.1M added.
  • The largest Genomic Health, Inc. seller in Q3 2016 was Baillie Gifford & Co, an estimated $15.9M sold.

Based on aggregated 13F filings for Q3 2016.